Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Marta Parera"'
Autor:
Marta Parera Roig, David Compte Colomé, Gemma Basagaña Colomer, Emilia Gabriela Sardo, Mauricio Alejandro Tournour, Silvia Griñó Fernández, Arturo Ivan Ominetti, Emma Puigoriol Juvanteny, José Luis Molinero Polo, Daniel Badia Jobal, Nadia Espejo-Herrera
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 2145-2157 (2024)
Non-small-cell lung cancer (NSCLC) has experienced several diagnostic and therapeutic changes over the past two decades. However, there are few studies conducted with real-world data regarding the evolution of the cost of these new drugs and the corr
Externí odkaz:
https://doaj.org/article/91e0c5c6c8fe421d80df10fbc6eac839
Autor:
Juan Ambrosioni, Omar Sued, David Nicolas, Marta Parera, María López-Diéguez, Anabel Romero, Fernando Agüero, María Ángeles Marcos, Christian Manzardo, Laura Zamora, Manuel Gómez-Carrillo, José María Gatell, Tomás Pumarola, José María Miró
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0125837 (2015)
To evaluate the prevalence of transmitted drug resistance (TDR) and non-B subtypes in patients with acute/recent HIV-1 infection in Barcelona during the period 1997-2012.Patients from the "Hospital Clínic Primary HIV-1 Infection Cohort" with a genot
Externí odkaz:
https://doaj.org/article/c827459b803d4b8ba0fa473ad7c7d5e2
Autor:
Roxana Reyes, Sergi Castillo, C. Cases, J. Mases, David Sánchez-Lorente, Maria Mayoral, Silvia Muñoz, Pilar Paredes, Marc Boada, Marta Parera-Roig, Carmen M. Lucena, Francesc Casas, Roberto Martin-Deleon, Daniel Martinez, M. Mollà, Diego Muñoz-Guglielmetti, Ivan Vollmer, Mariana Benegas
Publikováno v:
World Journal of Clinical Oncology. 12:1047-1063
Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC. Contribution of IASLC recommendations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46741c4dda440a09772393166d1ccf16
https://doi.org/10.5306/wjco.v12.i11.1047
https://doi.org/10.5306/wjco.v12.i11.1047
Autor:
Margarita Romeo, Marta Gil-Martín, Lydia Gaba, Iris Teruel, Álvaro Taus, Claudia Fina, Maria Masvidal, Paola Murata, Julen Fernández-Plana, Alejandro Martínez, Cristina Pérez, Yolanda García, Valerie Rodriguez, Sara Cros, Marta Parera, Montserrat Zanui, Silvia Catot, Beatriz Pardo, Andrea Plaja, Anna Esteve, Maria Pilar Barretina-Ginesta
Publikováno v:
Cancers
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Scientia
Cancers; Volume 14; Issue 18; Pages: 4414
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Scientia
Cancers; Volume 14; Issue 18; Pages: 4414
Simple Summary Since the irruption of PARPi in the therapeutic armamentarium for ovarian cancer, concerns regarding post-progression treatment outcomes have emerged, owing to known crossed-resistance mechanisms between PARPi and platinum. In this mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea56cb82745ed2816479a78c7958bbe4
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7061
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7061
Autor:
Andrea Vergara, Elisa Rubio, Clara Ballesté-Delpierre, Míriam José Alvarez Martinez, Genoveva Cuesta Chasco, Miguel J. Martínez, Yuliya Zboromyrska, M. Fernández, Adán Fernández, M Eugenia Valls, Aurea Mira, Marta Parera, Maria Angeles Marcos, Jordi Vila, Cristian Aylagas, Pilar Salvador, Climent Casals-Pascual, Berta Fidalgo, Victor Pastor
Publikováno v:
Journal of Medical Microbiology. 70
Introduction. The identification of enteropathogens is critical for the clinical management of patients with suspected gastrointestinal infection. The FLOW multiplex PCR system (FMPS) is a semi-automated platform (FLOW System, Roche) for multiplex re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::069ef0cc9ff80657b694eddeb4ea3a1b
https://doi.org/10.1099/jmm.0.001367
https://doi.org/10.1099/jmm.0.001367
Autor:
Diego, Muñoz-Guglielmetti, David, Sanchez-Lorente, Roxana, Reyes, Daniel, Martinez, Carmen, Lucena, Marc, Boada, Pilar, Paredes, Marta, Parera-Roig, Ivan, Vollmer, Joel, Mases, Roberto, Martin-Deleon, Sergi, Castillo, Mariana, Benegas, Silvia, Muñoz, Maria, Mayoral, Carla, Cases, Meritxell, Mollà, Francesc, Casas
Publikováno v:
World Journal of Clinical Oncology
BACKGROUND Neoadjuvant treatment (NT) with chemotherapy (Ch) is a standard option for resectable stage III (N2) NSCLC. Several studies have suggested benefits with the addition of radiotherapy (RT) to NT Ch. The International Association for the Stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7c5051a749f922daca0b1a24a17b74ce
https://pubmed.ncbi.nlm.nih.gov/34909399
https://pubmed.ncbi.nlm.nih.gov/34909399
Autor:
José Baselga, Marta Parera, Alejandro Javier García, Sergio Peralta, Antonio Gil-Moreno, J. M. Martinez-Palones, María A. Pérez-Benavente, J. M. Del Campo, Aleix Prat, B. Adamo
Publikováno v:
Annals of Oncology. 20:294-297
Background: Our group evaluated the risk of recurrence for optimally treated advanced epithelial ovarian cancer (adEOC) in patients with a low-level rising serum CA-125 concentration within the normal range (0-35 kU/I). In addition, we tested the new
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd16efdcc0981b59123638d2fcd6fe45
https://doi.org/10.1093/annonc/mdn601
https://doi.org/10.1093/annonc/mdn601
Publikováno v:
Gynecologic Oncology. 110:S72-S76
Effective cytotoxic treatment options for advanced cervical cancer are exceedingly limited. Cisplatin-based combination chemotherapy, the most commonly used cytotoxic therapy, has produced response rates ranging from 20% to 30% and overall survival o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d7170b07ce3fd1664babdf80d3668d
https://doi.org/10.1016/j.ygyno.2008.04.016
https://doi.org/10.1016/j.ygyno.2008.04.016
Autor:
José Baselga, Cristina Saura, Barbara Klughammer, Enriqueta Felip, Joachim Möcks, Federico Rojo, Dorothee Foernzler, Martin Reck, Gemma Sala, Sergio Peralta, Astrid Heller, Susana Cedres, Ulrich Gatzemeier, Marta Parera, Heiko Maacke
Publikováno v:
Clinical Cancer Research. 14:3867-3874
Purpose: To examine potential markers of clinical benefit and the effects of erlotinib on the epidermal growth factor receptor (EGFR) signaling pathway in advanced non–small cell lung cancer patients refractory to platinum-based chemotherapy. Exper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99af5e91cfb99856fec6bd19b412f3d7
https://doi.org/10.1158/1078-0432.ccr-07-5186
https://doi.org/10.1158/1078-0432.ccr-07-5186
Autor:
Pere Huguet, Sergio Peralta, Marta Parera, J. Andreu, Susana Cedres, Vicky Reyes, Aleix Prat, Josep M. del Campo
Publikováno v:
Head & Neck. 30:680-683
Background. Salivary ductal carcinoma (SDC) is an uncommon malignant tumor of the salivary glands. Although there is no known standard of care for the treatment of ad- vanced disease, the vast majority of patients with SDC may be offered palliative s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a9f6d592ba964f2c509c0bb1c991505
https://doi.org/10.1002/hed.20714
https://doi.org/10.1002/hed.20714